

6th Annual MarketsandMarkets Next-Gen Bioprocessing Conference - Shedding Light on a Key Pillar of Modern Medicine

PUNE, MH, INDIA, July 22, 2022

[/EINPresswire.com/](https://www.einpresswire.com/) -- The greatest challenges for the bioprocessing industry have always been the time taken from drug discovery to large scale manufacturing & the immense cost associated with it. Over the past decade, technological advancements have grown exponentially allowing the biopharma ecosystem to transform workflows & tackle these very problems.

[The 6th ANNUAL MARKETSANDMARKETS NEXT-GEN BIOPROCESSING CONFERENCE](#)

scheduled for the 6th-7th October 2022 in London, UK will home in on discussions, case studies & in-depth presentations on critical industry topics such as 'Cell Culture & Bioproduction', Downstream Processing & Continuous Biomanufacturing & 'Cell And Gene Therapy Analytics & Manufacturing'.

With key decision makers encompassing CEOs, CSOs, Head Investigators & leading on-field Researchers in attendance, the conference provides an unprecedented opportunity for cross-discipline networking across various vital domains of the bioprocessing industry. Having had time to reflect on the learning post-pandemic, these 2 days shall facilitate solutions to current & anticipated challenges & shed light on innovations leading the charge as the future unfolds before our eyes.

A SNIPPET OF THE TOPICS BEING DISCUSSED AT THE CONFERENCE



4TH ANNUAL
NEXT-GEN BIOPROCESSING CONFERENCE
20th-21st October 2022 | Boston
SIGN UP NOW. SEATS LIMITED

6th Annual MarketsandMarkets
NEXT - GEN BIOPROCESSING CONFERENCE
6th-7th October 2022
London

Key Highlights

- Stem cell transplantation for cellular aspects
- Culture technology for cell & Gene therapy applications
- Ex-vivo cell and gene therapy manufacturing
- Autologous gene therapy delivery
- Conventional Car-T cell delivery
- Allogenic Car-T cell therapy application
- Quality control in manufacturing of cell therapy
- Supply chain management for cell therapy management
- Regulatory and reimbursement issues based on GMP guidelines

CELL CULTURE & BIOPRODUCTION

- Protein synthesis and cell line development
- Bioprocess development strategies
- Process monitoring and control

DOWNSTREAM PROCESSING & CONTINUOUS BIOMANUFACTURING

- Enhancing protein purification
- Biomanufacturing 2030: The latest manufacturing shift
- Pharma 4.0 trends and new drug delivery strategies

CELL AND GENE THERAPY ANALYTICS & MANUFACTURING

- Emerging analytical methods & Quality Control
- AAV scale-up and manufacturing
- Navigating cell & gene therapy CMC and comparability

QUICK GLIMPSE OF OUR EXPERT SPEAKER PANEL

- Zhimei Du, Vice President, Allogeneic Cell Therapy, Atara Biotherapeutics
- Dimitrios A. Lamprou, Director - MSc Industrial Pharmaceutics, Queen's University Belfast
- Anthony Colenburg, Director of Quality, Adicet Bio, Inc
- John Maher, Chief Scientific Officer, Leucid Bio
- Ohad Karnieli, Founder and CEO, ADVA Biotechnology
- Paula Meleady, Associate Director, National Institute for Cellular Biotechnology
- Carmen Brenner, Director MSaT, Novadip

[VIEW THE REST OF OUR SPEAKERS & 2-DAY AGENDA HERE!](#)

[REGISTER FOR THE CONFERENCE TODAY!](#)

"MarketsandMarkets Events is impacting the revenue of global companies with our multitude of services in market research, consulting & conferences. We produce global conferences, summits and congresses bringing together industry leaders, key decision makers & clients worldwide across various industries, fostering exchange of ideas and latest research through cutting edge conference programs, interactive panels and round table discussions.

Our prominent events enable our participants to benefit through their revenue planning and help them take their innovations/disruptions early to the market by providing them industry-specific platforms to learn, network and showcase trending innovations of the industry to stay ahead on the competition curve."

Ayush Kanitkar

MarketsandMarkets

+91 89759 85061

events@marketsandmarkets.com

This press release can be viewed online at: <https://www.einpresswire.com/article/582197240>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.